文献速递前列腺癌

AUA政策声明:多参数磁共振成像在前列腺癌诊断、分期和管理中的应用

AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer.
PubMed 文献 · J Urol · 2017-05-05

AUA专家组基于现有文献评估多参数磁共振成像在前列腺癌筛查、诊断、分期和监测中的临床与经济有效性。数据显示既往穿刺阴性但持续担忧前列腺癌风险者支持使用磁共振成像;初次穿刺数据提示某些情况下可能有作用;目前证据不足以推荐用于筛查、分期或监测。

要点

  • 既往穿刺阴性且持续担忧前列腺癌风险者,数据支持使用磁共振成像。
  • 初次穿刺使用磁共振成像的数据提示某些情况下可能有作用。
  • 目前证据不足以推荐磁共振成像用于前列腺癌筛查、分期或监测。

核心结论

  • 磁共振成像虽增加前列腺癌管理成本,但提供更优解剖细节并可评估细胞密度和血流。
  • 影像靶向穿刺通过识别常规超声不可见病灶可能增加有临床意义前列腺癌的诊断。
  • 磁共振成像在前列腺癌管理中的临床适应证正在快速演变。

研究设计与样本

  • 由前列腺癌诊断与管理专家组成的小组评估已发表文献。
  • 有充分研究可分析时基于数据提出推荐,无充分研究时基于专家共识提出推荐。

主要发现

  • 数据支持对既往穿刺阴性且持续担忧前列腺癌风险者使用磁共振成像。
  • 初次穿刺相关数据提示磁共振成像在某些情况下可能有作用。
  • 目前证据不足以推荐磁共振成像用于前列腺癌筛查、分期或监测。

关键数值与推荐

  • 有充分研究可分析时基于数据提出推荐。
  • 无充分研究可分析时基于专家共识提出推荐。

临床怎么用

  • 对既往穿刺阴性且持续担忧前列腺癌风险者,数据支持使用磁共振成像。
  • 对初次穿刺者,磁共振成像在某些情况下可能有作用。
  • 目前证据不足以推荐磁共振成像用于筛查、分期或监测。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We summarize the available data about the clinical and economic effectiveness of magnetic resonance imaging in the diagnosis and management of prostate cancer, and provide practical recommendations for its use in the screening, diagnosis, staging and surveillance of prostate cancer. MATERIALS AND METHODS: A panel of clinicians with expertise in the diagnosis and management of prostate cancer evaluated the current published literature on the use and effectiveness of magnetic resonance imaging for this disease. When adequate studies were available for analysis, recommendations were made on the basis of data and when adequate studies were not available, recommendations were made on the basis of expert consensus. RESULTS: At this time the data support the use of magnetic resonance imaging in patients with a previous negative biopsy and ongoing concerns about increased risk of prostate cancer. The data regarding its usefulness for initial biopsy suggest a possible role for magnetic resonance imaging in some circumstances. There is currently insufficient evidence to recommend magnetic resonance imaging for screening, staging or surveillance of prostate cancer. CONCLUSIONS: Although it adds cost to the management of prostate cancer, magnetic resonance imaging offers superior anatomic detail, and the ability to evaluate cellular density based on water diffusion and blood flow based on contrast enhancement. Imaging targeted biopsy may increase the diagnosis of clinically significant cancers by identifying specific lesions not visible on conventional ultrasound. The clinical indications for the use of magnetic resonance imaging in the management of prostate cancer are rapidly evolving.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Fulgham PF, Rukstalis DB, Turkbey IB, et al. AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2017. PMID: 28483574. doi:10.1016/j.juro.2017.04.101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。